cannabidiol sulphate

Cannabidiol sulphate (LRP-661, CBDS) is a semi-synthetic, orally available derivative of cannabidiol (CBD) developed by London Research & Pharmaceuticals. It is designed to offer improved oral bioavailability and predictable pharmacokinetics compared to standard CBD formulations. LRP-661 demonstrates superior safety and efficacy in preclinical epilepsy models—including PTZ kindled mice and maximal electroshock seizure tests—showing enhanced gastrointestinal tolerability and absence of liver or renal toxicity relative to existing oral CBD solutions such as Epidiolex. The drug’s formulation allows for tablet and water-based solutions rather than oil suspensions. Its primary indication is epilepsy, with orphan drug applications being prepared for Dravet syndrome and Lennox-Gastaut syndrome[1][2][5][7].

Other names

cannabidiol sulphateCBD sulphate